C. La and . Émettra-un-avis-d-'efficience-sur-le-médicament, L'efficience de ce dernier pour la société sera mesurée grâce à la comparaison des moyens employés (coûts) avec les résultats obtenus

P. Au, J. Officiel, and L. , arrêté d'inscription de l'anticorps anti-intégrine ?4ß7 sur la liste des médicaments remboursables ainsi que les avis de fixation du taux de remboursement et du prix seront publiés de façon

P. Lapaquette, P. Brest, and P. Hofman, Etiology of Crohn???s disease: many roads lead to autophagy, Journal of Molecular Medicine, vol.3, issue.9, pp.987-96, 2012.
DOI : 10.1007/s00109-012-0934-8

R. Sartor, Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis, Nature Clinical Practice Gastroenterology & Hepatology, vol.124, issue.7
DOI : 10.1038/ncpgasthep0528

Y. Zhang and Y. Li, Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014.
DOI : 10.3748/wjg.v20.i1.91

V. Benedini, N. Caporaso, and G. Corazza, Burden of Crohn's disease : economics and quality of life aspects in Italy, ClinicoEcon Outcomes Res, vol.4, pp.209-227, 2012.

L. Wallace, B. Zheng, Y. Kanasawa, and D. Shih, Immunopathology of inflammatory bowel disease, World Journal of Gastroenterology, vol.20, issue.1, pp.6-21, 2014.
DOI : 10.3748/wjg.v20.i1.6

N. Molodecky, I. Soon, and D. Rabi, Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012.
DOI : 10.1053/j.gastro.2011.10.001

J. Blanchard, C. Bernstein, A. Wajda, and P. Rawsthorne, Small-area Variations and Sociodemographic Correlates for the Incidence of Crohn's Disease and Ulcerative Colitis, American Journal of Epidemiology, vol.154, issue.4
DOI : 10.1093/aje/154.4.328

L. Jr, E. V. Schoenfeld, P. Sandborn, and W. , The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America/ a systematic review, Aliment Pharmacol Ther, vol.16, pp.51-60, 2002.

C. Gismera and B. Aladren, Inflammatory bowel diseases : a disease(s) of modern times ? Is incidence still increasing ?, World J Gastroenterol, vol.14, issue.1036, pp.5491-5499, 2008.

D. Kappelman, R. Moore, K. , and K. A. Jeffery, Recent Trends in the Prevalence of Crohn???s Disease and Ulcerative Colitis in a Commercially Insured US Population, Digestive Diseases and Sciences, vol.132, issue.2, pp.519-525, 2013.
DOI : 10.1007/s10620-012-2371-5

R. W. Leong, Y. Lau, J. , J. Sung, and J. , The Epidemiology and Phenotype of Crohn???s Disease in the Chinese Population, Inflammatory Bowel Diseases, vol.10, issue.5, pp.646-51, 2004.
DOI : 10.1097/00054725-200409000-00022

C. R. Victoria, S. L. Nunes, and H. R. , Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of S??o Paulo State, Brazil, midwester of Sao Paulo State, pp.20-25, 2009.
DOI : 10.1590/S0004-28032009000100009

?. Hovde and B. Moum, Epidemiology and clinical course of Crohn's disease: Results from observational studies, World Journal of Gastroenterology, vol.18, issue.15, pp.1723-1731, 2012.
DOI : 10.3748/wjg.v18.i15.1723

R. Baldassano and D. Piccoli, INFLAMMATORY BOWEL DISEASE IN PEDIATRIC AND ADOLESCENT PATIENTS, Gastroenterology Clinics of North America, vol.28, issue.2, pp.445-58, 1999.
DOI : 10.1016/S0889-8553(05)70064-9

J. Markowitz, Patterns of Complementary and Alternative Medicine Use in a Population of Pediatric Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.5, pp.599-605, 2004.
DOI : 10.1097/00054725-200409000-00015

G. Lichtenstein, Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease, Inflammatory Bowel Diseases, vol.7, issue.S1, pp.23-32, 2001.
DOI : 10.1002/ibd.3780070506

M. Allez, K. Karmiris, and E. Louis, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects, Journal of Crohn's and Colitis, vol.4, issue.4, pp.355-66, 2010.
DOI : 10.1016/j.crohns.2010.04.004

E. Stange, S. Travis, and S. Vermeire, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, Gut, vol.55, issue.suppl_1, pp.5-15, 2006.
DOI : 10.1136/gut.2005.081950a

L. Takeda and . Pipeline, Disponible sur <http (22) Amgen Website Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio. [en ligne] Disponible sur : http://wwwext.amgen.com/media/media_pr_detail.jsp?releaseID=1679295 (23) European Medicines Agency (EMA). Entyvio. Autorisation details, Disponible sur, p.278, 2014.

S. Gosh and R. Panaccione, Review: Anti-adhesion molecule therapy for inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.354, issue.2, pp.2-001751
DOI : 10.1177/1756283X10373176

W. Pan, K. Köck, and W. Rees, antibody that specifically alters trafficking of gut-homing T cells, British Journal of Pharmacology, vol.60, issue.S1, pp.51-68, 2013.
DOI : 10.1111/bph.12134

E. Commission, Notice to Applicants, medicinal products for human use, Disponible sur, pp.5-2008, 2008.

). Watanabe, General Overview of eCTD [en ligne]. [ Consulté le 10, Disponible sur, 2011.

. Disponible-sur, Quality of biotechnological products: Viral safety evaluation of biotechnological products derived from cell lines of human or animal origins, 2014.

E. Bwp, Disponible sur Guideline on virus safety evaluation of investigational medicinal products, Disponible sur, 2005.

C. Bwp, Concept paper on the revision of the guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins CHMP, Disponible sur C500003603.pdf (35) European Medicines Agency (EMA) 2014. [en ligne]. [Consulté le 17 Disponible sur, 1999.

/. Wc500163623, pdf (36) ICH.Preclinical safety evaluation of biotechnology-derived pharmaceutical S6(R1), 1997.

C. Horvath and N. Milton, Disponible sur : http://www.ich.org/fileadmin The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?, Toxicol Pathol, vol.17, issue.373, pp.372-83, 2009.

A. Mantovani and A. Naghavi, PARALLEL IMPORTS AND INNOVATION IN AN EMERGING ECONOMY: THE CASE OF INDIAN PHARMACEUTICALS, Health Economics, vol.42, issue.4, pp.1286-99, 2012.
DOI : 10.1002/hec.1790

P. C. Le, Le marché pharmaceutique dans le monde et en France : Bilan et Perspective, 2009.

K. Dada, M. Kremzner, and K. Bhanot, Role of FDA's drug information centers, American Journal of Health-System Pharmacy, vol.65, issue.9, pp.803-808, 2008.
DOI : 10.2146/ajhp070525

J. Wilson, C. Hair, R. Knight, and . Etal, High incidence of inflammatory bowel disease in

. Australia, a prospective population base australian incidence study, Inflamm Bowel Dis, vol.16, pp.1550-1556, 2010.

U. Colitis-gearry, R. Richardson, A. Frampton, and C. , High incidence of Crohn??s disease in Canterbury, New Zealand: Results of an epidemiologic study, Inflammatory Bowel Diseases, vol.12, issue.10, pp.936-979, 2006.
DOI : 10.1097/01.mib.0000231572.88806.b9

M. Pavic, A. Pfeil, and T. Szucs, Estimating the Potential Annual Welfare Impact of Innovative Drugs in Use in Switzerland, Frontiers in Public Health, vol.10, issue.48, p.48, 2014.
DOI : 10.3389/fpubh.2014.00048

P. Frei, L. Biedermann, and G. Rogler, Maladie de Crohn et colite ulcéreuse -l'essentiel pour les non-gastro-entérologues, Forum Med Suisse, vol.11, issue.47, pp.718-744, 2011.

M. Shirotani, T. Suwa, T. Kurokawa, and K. Chiba, Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials, The Journal of Clinical Pharmacology, vol.42, issue.2, pp.438-483, 2014.
DOI : 10.1002/jcph.216

R. Hill and M. Chui, The pharmerging future. The business magazine of Pharma, 2009.

L. Castanheira, D. Barbano, and N. Rech, Current development in regulation of similar biotherapeutic products in Brazil, Biologicals, vol.39, issue.5, pp.308-319, 2011.
DOI : 10.1016/j.biologicals.2011.06.021

M. Russel, Changes in the incidence of inflammatory bowel disease: what does it mean? European journal of internal medicine, pp.191-197, 2000.

J. Hyams, J. Markowitz, and A. Otley, Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience, Journal of Pediatric Gastroenterology and Nutrition, vol.41, issue.4, pp.416-437, 2005.
DOI : 10.1097/01.mpg.0000183350.46795.42

M. Silverstein, E. Loftus, and W. Sandborn, Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort, Gastroenterology, vol.117, issue.1, pp.49-57, 1999.
DOI : 10.1016/S0016-5085(99)70549-4

R. Hilsden, M. Verhoef, and A. Best, A national survey on the patterns of treatment of inflammatory bowel disease in Canada, BMC Gastroenterology, vol.95, issue.1, p.10, 20035.
DOI : 10.1111/j.1572-0241.2000.02261.x

P. Gibson, A. Weston, and A. Shann, Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease, Journal of Gastroenterology and Hepatology, vol.32, issue.8, pp.1306-1318, 2007.
DOI : 10.1097/01.MIB.0000218762.61217.4a

B. Feagan, M. Vreeland, and L. Larson, Annual cost of care for Crohn's disease: a payor perspective, The American Journal of Gastroenterology, vol.117, issue.8, pp.1955-60, 2000.
DOI : 10.1111/j.1572-0241.2000.01779.x

J. Hay and A. Hay, Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, vol.14, issue.4, pp.309-326, 1992.
DOI : 10.1097/00004836-199206000-00009

A. Bassi, S. Dodd, and P. Williamson, Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study, Gut, vol.53, issue.10, pp.1471-1479, 2004.
DOI : 10.1136/gut.2004.041616

G. Lichtenstein, S. Yan, and M. Bala, Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries, The American Journal of Gastroenterology, vol.7, issue.10, pp.91-97, 2004.
DOI : 10.1111/j.1572-0241.2001.03878.x

S. Vardi, H. Friger, and M. , Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification, J Crohn's Colitis, vol.1, issue.2, pp.87-96, 2007.

S. Friger, M. Vardi, H. Claessens, and G. , Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease, Inflamm Bowel Dis, vol.13, issue.7, pp.874-81, 2007.

M. Kappelman, S. Rifas-shiman, and C. Porter, Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults, Gastroenterology, vol.135, issue.6, pp.1907-1920, 2008.
DOI : 10.1053/j.gastro.2008.09.012

C. Bernstein, E. Loftus, . Jr, and S. Ng, Hospitalisations and surgery in Crohn's disease, Gut, vol.61, issue.4
DOI : 10.1136/gutjnl-2011-301397

T. Longobardi and C. Bernstein, Health Care Resource Utilization in Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.731-774, 2006.
DOI : 10.1016/j.cgh.2006.02.013

C. Bernstein, T. Longobardi, and G. Finlayson, Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study, Inflammatory Bowel Diseases, vol.18, issue.8, pp.1498-508, 2011.
DOI : 10.1002/ibd.21878

P. Blomqvist and A. Ekbom, Inflammatory Bowel Diseases: Health Care and Costs in Sweden in 1994, Scandinavian Journal of Gastroenterology, vol.13, issue.24, pp.1134-1143, 1997.
DOI : 10.1097/00004836-199206000-00010

S. Canada, Décès selon la cause, Chapitre XI : Maladies de l'appareil digestif (K00 à K93) le groupe d'âge et le sexe, Canada, annuel (nombre) Tableau, pp.102-0531

F. Michael, . Drummond, J. Bernie, G. O-'brien, . Lstoddart et al., related-connexes-fra.htm (73), www.statcan.gc.ca, 2008000.

E. Paris and . Economica, Guide méthodologiques ;Choix méthodologiques pour l'évaluation économique à la HAS [en ligne]. [Consulté le 23/06 Disponible sur : http://www.hassante .fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf (75) : Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l'article L.162-16-6 du code de la sécurité sociale, 1998.

U. S. Takeda-pharmaceuticals, . Inc, J. Gregor, J. Mcdonald, and N. Klar, Briefing document for the joint meeting of the gastrointestinal drugs advisory committee and drug safety committee and risk management advisory committee. 2013. [en ligne]. [Consulté le 24 An evaluation of utility measurement in Crohn's disease, Disponible sur, pp.265-76, 1997.

I. Jaisson-hot, B. Flourié, and L. Descos, Management for severe Crohn's disease: A lifetime cost-utility analysis, International Journal of Technology Assessment in Health Care, vol.88, issue.03, pp.274-283, 2004.
DOI : 10.1016/S0140-6736(78)92524-2

J. Massol, A. Puech, and J. Boissel, Comment anticiper l'évaluation de l'intérêt de santé publique des médicaments ? Thérapie, pp.417-442, 2007.

H. Autorité and D. Santé, Unité méthodologie et études post-inscription : Les études post-inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes)

H. Autorité and D. Santé, Avis d'efficience : Etapes d'élaboration

H. Autorité and D. Santé, Avis d'efficience : Format de l'avis d'efficience